Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about EXOSOME: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | EXOSOME |
| Key Genes/Proteins | ADAM10, AKT, APOE, APP, BAX, BDNF |
| Related Diseases | AGING, ALS, ALZHEIMER, Alzheimer's disease, ALZHEIMER'S DISEASE |
Knowledge base pages for this entity
graph TD
EXOSOME[EXOSOME]
EXOSOME -->|interacts| Crispr[Crispr]
EXOSOME -->|mediates| intercellular_communication[intercellular communication]
EXOSOME -.biomarker for.-> Alzheimer_s_disease[Alzheimer's disease]
EXOSOME -->|involved_in| Intercellular_Communication[Intercellular Communication]
EXOSOME -->|activates| FOXO3[FOXO3]
EXOSOME -->|regulates| TAU[TAU]
EXOSOME -->|regulates| CELL_DEATH[CELL DEATH]
EXOSOME -->|inhibits| LYSOSOMAL_DYSFUNCTION[LYSOSOMAL DYSFUNCTION]
EXOSOME -->|regulates| MACROPHAGES[MACROPHAGES]
EXOSOME -->|treats| CHOLESTEROL[CHOLESTEROL]
multivesicular_endosome[multivesicular endosome] -->|involved_in| EXOSOME
NTN1[NTN1] -->|component_of| EXOSOME
TFEB[TFEB] -->|inhibits| EXOSOME
METASTASIS[METASTASIS] -->|activates| EXOSOME| Target | Relation | Type | Str |
|---|---|---|---|
| miR-522 | associated_with | compound | 0.90 |
| Crispr | interacts_with | drug | 0.85 |
| Alzheimer's disease | biomarker_for | disease | 0.80 |
| intercellular communication | mediates | process | 0.80 |
| Intercellular Communication | involved_in | process | 0.75 |
| FOXO3 | activates | gene | 0.70 |
| TAU | regulates | protein | 0.70 |
| CELL DEATH | regulates | phenotype | 0.70 |
| CHOLESTEROL | treats | phenotype | 0.65 |
| MACROPHAGES | regulates | cell_type | 0.65 |
| LYSOSOMAL DYSFUNCTION | inhibits | phenotype | 0.65 |
| VEGF | associated_with | gene | 0.50 |
| AGING | associated_with | phenotype | 0.50 |
| ALS | associated_with | disease | 0.50 |
| PRION | associated_with | protein | 0.50 |
| CORTEX | associated_with | brain_region | 0.50 |
| TDP-43 | associated_with | gene | 0.50 |
| ADAM10 | associated_with | gene | 0.50 |
| P-TAU | associated_with | protein | 0.50 |
| APOE | associated_with | gene | 0.50 |
| CD33 | associated_with | gene | 0.50 |
| TNF | associated_with | gene | 0.50 |
| STAT3 | associated_with | gene | 0.50 |
| PI3K | associated_with | gene | 0.50 |
| JAK2 | associated_with | gene | 0.50 |
| MFN2 | associated_with | gene | 0.50 |
| AKT | associated_with | gene | 0.50 |
| FOXO3 | associated_with | gene | 0.50 |
| BAX | associated_with | gene | 0.50 |
| JNK | associated_with | gene | 0.50 |
| TREM2 | associated_with | gene | 0.50 |
| TFEB | associated_with | gene | 0.50 |
| CX3CR1 | associated_with | gene | 0.50 |
| GPX4 | associated_with | gene | 0.45 |
| LRRK2 | associated_with | gene | 0.45 |
| CSF | associated_with | phenotype | 0.45 |
| NLRP3 | associated_with | gene | 0.45 |
| APP | associated_with | gene | 0.45 |
| S100B | associated_with | gene | 0.45 |
| ROS | associated_with | phenotype | 0.45 |
| TAU | associated_with | protein | 0.45 |
| CANCER | associated_with | disease | 0.45 |
| NEURON | associated_with | cell_type | 0.45 |
| BDNF | associated_with | gene | 0.45 |
| Source | Relation | Type | Str |
|---|---|---|---|
| Multivesicular Endosome | associated_with | cell_type | 0.95 |
| multivesicular endosome | involved_in | cell_type | 0.95 |
| NTN1 | component_of | protein | 0.90 |
| TFEB | inhibits | gene | 0.70 |
| METASTASIS | activates | phenotype | 0.65 |
| MICROGLIAL ACTIVATION | associated_with | phenotype | 0.50 |
| NEURODEGENERATION | associated_with | phenotype | 0.50 |
| NEUROINFLAMMATION | associated_with | phenotype | 0.50 |
| TEMPORAL LOBE | associated_with | brain_region | 0.50 |
| PHAGOCYTOSIS | associated_with | phenotype | 0.50 |
| PARKINSON | associated_with | disease | 0.50 |
| CYTOKINES | associated_with | phenotype | 0.50 |
| DEMENTIA | associated_with | disease | 0.50 |
| LEWY BODY DEMENTIA | associated_with | disease | 0.50 |
| NEURONS | associated_with | cell_type | 0.50 |
| CYP46A1 | associated_with | gene | 0.50 |
| CELL DEATH | associated_with | phenotype | 0.50 |
| APOPTOSIS | associated_with | phenotype | 0.50 |
| MICROGLIA | associated_with | cell_type | 0.50 |
| MONOCYTES | associated_with | cell_type | 0.45 |
| CHOLESTEROL | associated_with | phenotype | 0.45 |
| OBESITY | associated_with | disease | 0.45 |
| INFLAMMATION | associated_with | phenotype | 0.45 |
| CERAMIDE | associated_with | phenotype | 0.45 |
| HIPPOCAMPUS | associated_with | brain_region | 0.45 |
| NLRP3 INFLAMMASOME | associated_with | pathway | 0.45 |
| TUMOR MICROENVIRONMENT | associated_with | phenotype | 0.45 |
| UBIQUITIN | associated_with | protein | 0.45 |
| HNRNPA1 | associated_with | gene | 0.45 |
| PODOCYTES | associated_with | cell_type | 0.45 |
| AUTOPHAGY | associated_with | phenotype | 0.45 |
| HEPATOCELLULAR CARCINOMA | associated_with | disease | 0.45 |
| METASTASIS | associated_with | phenotype | 0.45 |
| LACTATE | associated_with | phenotype | 0.45 |
| LYSOSOMAL DYSFUNCTION | associated_with | phenotype | 0.45 |
| FIBROBLASTS | associated_with | cell_type | 0.45 |
| FERROPTOSIS | associated_with | phenotype | 0.45 |
| ALZHEIMER'S DISEASE | associated_with | disease | 0.45 |
| ALZHEIMER | associated_with | disease | 0.45 |
| ASTROCYTE | associated_with | cell_type | 0.45 |
| ENDOTHELIAL CELLS | associated_with | cell_type | 0.45 |
| MACROPHAGE | associated_with | cell_type | 0.45 |
| ISCHEMIA | associated_with | disease | 0.45 |
| MACROPHAGES | associated_with | cell_type | 0.45 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-00 | 0.938 | molecular neurobiology | View |
| P2RX7-Mediated Exosome Secretion Blockade | 0.807 | neurodegeneration | Tau propagation mechanisms and therapeut |
| Microglial Exosome-Mediated Tau Propagation | 0.702 | neuroscience | Circuit-level neural dynamics in neurode |
| TNFRSF25-Mediated Aging Exosome Pathway Inhibition | 0.587 | neurodegeneration | Gene expression changes in aging mouse b |
| Gamma-Entrained PV Interneuron Networks Enable Precision p-t | 0.536 | molecular neurobiology | View |
| Gamma-Entrained PV Interneurons Enable Precision p-tau217-Gu | 0.461 | molecular neurobiology | View |
| CSF Neurofilament Light-Triggered Astrocyte-Derived Exosome | 0.460 | molecular neurobiology | View |
| Gamma-Entrained P-tau217 Biomarker Cascades Optimize lncRNA- | 0.431 | molecular neurobiology | View |
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| P2rx7 genetic deletion in PS19 tauopathy mice | validation | Alzheimer's disease/tauopathy | 0.900 | 0.00 | PS19 tauopathy mice | proposed | N/A |
| P2rx7 congenic mouse model insulin tolerance testing | validation | insulin resistance | 0.900 | 0.00 | congenic mice (C57BL6 P2rx7 al | proposed | N/A |
| P2rx7 congenic mouse model glucose tolerance testing | validation | glucose intolerance | 0.900 | 0.00 | congenic mice (C57BL6 P2rx7 al | proposed | N/A |
| Single-cell RNA sequencing of mouse brains | exploratory | Alzheimer's disease/tauopathy | 0.900 | 0.00 | PS19 mouse brain tissue | proposed | N/A |
| P2RX7 variant rs1718119 association with glucose homeostasis in Botnia | exploratory | type 2 diabetes | 0.900 | 0.00 | human patients | proposed | N/A |
| Cell type-specific P2rx7 deletion in microglia vs astrocytes | validation | Alzheimer's disease/tauopathy | 0.850 | 0.00 | PS19 mice with cell type-speci | proposed | N/A |
| Brain-derived extracellular vesicles proteome analysis | exploratory | Alzheimer's disease/tauopathy | 0.850 | 0.00 | Brain-derived extracellular ve | proposed | N/A |
| BDEV injection and recipient microglial transcriptome analysis | validation | Alzheimer's disease/tauopathy | 0.800 | 0.00 | Recipient mice injected with B | proposed | N/A |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Death receptor 3: A paradoxical biomarker and therapeutic target in pan-cancer. [PMID:41605339] | Fang W, Du J, Xu Z, Liu Q, Liu Y et al. | Crit Rev Oncol Hematol | 2026 | 0 |
| Homocysteine as a biomarker in arthritis and depression: Evidence from NHANES an [PMID:41693749] | Deng C, He Z, Zhu X | SAGE Open Med | 2026 | 0 |
| The involvement of TNFRSF25 in age-related hearing loss. [PMID:41882185] | Roche MV, Tang PC, Yan D, De Marchena MR | Hum Genet | 2026 | 0 |
| Maternal immune activation perturbs intestinal niche through microbial glyceroph [PMID:41926285] | Chang H, Zhu X, Shen C, Xu X, Ni Y et al | Cell Rep | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning EXOSOME in their description or question text
Score: 0.461 · molecular neurobiology · 2026-04-21
## Mechanistic Overview Gamma-Entrained PV Interneurons Enable Precision p-tau217-Guided lncRNA Exosome Therapy in Early
Score: 0.460 · molecular neurobiology · 2026-04-21
## Mechanistic Overview CSF Neurofilament Light-Triggered Astrocyte-Derived Exosome Dosing Maximizes lncRNA-0021 Therape
Score: 0.431 · molecular neurobiology · 2026-04-21
## Mechanistic Overview Gamma-Entrained P-tau217 Biomarker Cascades Optimize lncRNA-9969 Exosome Therapy Precision in Ea